IMPS-30 NOVEL AND SHARED NEOANTIGEN FOR GLIOMA T CELL THERAPY DERIVED FROM HISTONE 3 VARIANT H3.3 K27M MUTATION

Documenti analoghi

• Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation
  di: Hou, Yafei, et al.
  Pubblicazione: (2015)
• HG-81 NOVEL AND SHARED NEOANTIGEN FOR GLIOMA T CELL THERAPY DERIVED FROM HISTONE 3 VARIANT H3.3 K27M MUTATION
  di: Kohanbash, Gary, et al.
  Pubblicazione: (2016)
• IMMU-41. H3.3K27M MUTATION-DERIVED NOVEL NEOANTIGEN – CHARACTERIZATION OF THE HLA-A2-BINDING EPITOPE AND A SPECIFIC T CELL RECEPTOR FOR DEVELOPMENT OF T CELL-BASED IMMUNOTHERAPY
  di: Chheda, Zinal, et al.
  Pubblicazione: (2017)
• Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy
  di: Chheda, Zinal S., et al.
  Pubblicazione: (2018)
• IMPS-11 EXPRESSION AND PROGNOSTIC IMPACT OF IMMUNE MODULATORY MOLECULE PD-L1 IN MENINGIOMA
  di: Han, Seunggu, et al.
  Pubblicazione: (2015)